A Multicentre, Prospective, Open-label, Non-comparative Study - Trial NCT06067256
Access comprehensive clinical trial information for NCT06067256 through Pure Global AI's free database. This Phase 4 trial is sponsored by Italfarmaco and is currently Recruiting. The study focuses on Contraception. Target enrollment is 228 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Italfarmaco
Timeline & Enrollment
Phase 4
Jul 20, 2023
Jun 01, 2024
Primary Outcome
Cycle control evaluation parameter
Summary
As there are no recent studies conducted in Italy on the profile of this COC, the purpose of
 this study is to evaluate its efficacy and tolerability in a given subset of women residing
 in Italy that are in need of contraception. Evaluate the cycle control: breakthrough bleeding
 (bleeding and/or spotting between cyclically regular onset of menses) of monophasic oral
 contraceptive pill Effimia® (NGM250 + EE35) in a population of women residing in Italy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06067256
Non-Device Trial